These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 4008047)

  • 1. Immunoregulation in experimental murine candidiasis: specific suppression induced by Candida albicans cell wall glycoprotein.
    Carrow EW; Domer JE
    Infect Immun; 1985 Jul; 49(1):172-81. PubMed ID: 4008047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mannan as an antigen in cell-mediated immunity (CMI) assays and as a modulator of mannan-specific CMI.
    Domer JE; Garner RE; Befidi-Mengue RN
    Infect Immun; 1989 Mar; 57(3):693-700. PubMed ID: 2917780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunodeficient CBA/N mice respond effectively to Candida albicans.
    Carrow EW; Hector RF; Domer JE
    Clin Immunol Immunopathol; 1984 Dec; 33(3):371-80. PubMed ID: 6388927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced immune responses in mice treated with penicillin-tetracycline or trimethoprim-sulfamethoxazole when colonized intragastrically with Candida albicans.
    Domer JE; Hector RF
    Antimicrob Agents Chemother; 1987 May; 31(5):691-7. PubMed ID: 3300536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of cyclophosphamide on murine candidiasis.
    Moser SA; Domer JE
    Infect Immun; 1980 Feb; 27(2):376-86. PubMed ID: 6991413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experimental murine candidiasis: cell-mediated immunity after cutaneous challenge.
    Moser SA; Domer JE; Mather FJ
    Infect Immun; 1980 Jan; 27(1):140-9. PubMed ID: 6987165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo immune responses to Candida albicans modified by treatment with recombinant murine gamma interferon.
    Garner RE; Kuruganti U; Czarniecki CW; Chiu HH; Domer JE
    Infect Immun; 1989 Jun; 57(6):1800-8. PubMed ID: 2498208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of a vaccine composed of heat-killed Candida albicans and a novel mucosal adjuvant, LT(R192G), against systemic candidiasis.
    Cárdenas-Freytag L; Cheng E; Mayeux P; Domer JE; Clements JD
    Infect Immun; 1999 Feb; 67(2):826-33. PubMed ID: 9916097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of effect of Candida albicans mannan on development of protective immune responses in experimental murine candidiasis.
    Garner RE; Domer JE
    Infect Immun; 1994 Feb; 62(2):738-41. PubMed ID: 7507901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experimental murine candidiasis: pathological and immune responses to cutaneous inoculation with Candida albicans.
    Giger DK; Domer JE; McQuitty JT
    Infect Immun; 1978 Feb; 19(2):499-509. PubMed ID: 344213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intragastric colonization of infant mice with Candida albicans induces systemic immunity demonstrable upon challenge as adults.
    Domer JE
    J Infect Dis; 1988 May; 157(5):950-8. PubMed ID: 3283263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased resistance in BALB/c mice to reinfection with Candida albicans is due to immunoneutralization of a virulence-associated immunomodulatory protein.
    Tavares D; Ferreira P; Arala-Chaves M
    Microbiology (Reading); 2003 Feb; 149(Pt 2):333-339. PubMed ID: 12624195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Candida-specific cell-mediated immunity is demonstrable in mice with experimental vaginal candidiasis.
    Fidel PL; Lynch ME; Sobel JD
    Infect Immun; 1993 May; 61(5):1990-5. PubMed ID: 8097493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune responses to Candida albicans in genetically distinct mice.
    Hector RF; Domer JE; Carrow EW
    Infect Immun; 1982 Dec; 38(3):1020-8. PubMed ID: 6759403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonspecific and Candida-specific immune responses in mice suppressed by chronic administration of anti-mu.
    Kuruganti U; Henderson LA; Garner RE; Asofsky R; Baker PJ; Domer JE
    J Leukoc Biol; 1988 Nov; 44(5):422-33. PubMed ID: 3141542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abrogation of suppression of delayed hypersensitivity induced by Candida albicans-derived mannan by treatment with monophosphoryl lipid A.
    Domer JE; Human LG; Andersen GB; Rudbach JA; Asherson GL
    Infect Immun; 1993 May; 61(5):2122-30. PubMed ID: 8478102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological activities of a Candida albicans protein which plays an important role in the survival of the microorganism in the host.
    Tavares D; Salvador A; Ferreira P; Arala-Chaves M
    Infect Immun; 1993 May; 61(5):1881-8. PubMed ID: 8478077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Candida-specific Th1-type responsiveness in mice with experimental vaginal candidiasis.
    Fidel PL; Lynch ME; Sobel JD
    Infect Immun; 1993 Oct; 61(10):4202-7. PubMed ID: 8406809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experimental murine candidiasis: cell-mediated immunity after cutaneous challenge.
    Domer JE; Moser SA
    Infect Immun; 1978 Apr; 20(1):88-98. PubMed ID: 352940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A mannoprotein constituent of Candida albicans that elicits different levels of delayed-type hypersensitivity, cytokine production, and anticandidal protection in mice.
    Mencacci A; Torosantucci A; Spaccapelo R; Romani L; Bistoni F; Cassone A
    Infect Immun; 1994 Dec; 62(12):5353-60. PubMed ID: 7960114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.